Collaborations in development and implementation of enabling technology to support PR&D



Council for Chemical Research June 2013 Henry Dubina



Challenges in Today's Pharma Industry

- Development costs continue to increase
- Synthetic targets increasing in complexity
- Increased regulatory demands
- High candidate attrition rate
- Cost pressures
 - Higher manufacturing costs
 - Lower payer costs
- Major patent expirations
- Cost competitive R&D
- R&D funding shift from small to larger molecules
- Patient outcomes based on value becoming the major driver

As pressures on the industry increase, new methods of working are required.

MTAC – a Pathway to Innovation

Early Phase Development



- Develop compounds
- Establish route
- Provide material early phase clinical trials

Design and Process Development



- Develop the process
 - Optimized
 - Safe
 - Robust

Scale-up and Manufacturing



- Establish scalable parameters
- Reduce batch failures
- Reduce cycle time

METTLER TOLEDO works with industry to address these challenges, providing solutions that deliver:

Faster

Lower Cost

Higher Quality

Increased Knowledge

METTLER BOLEDO CONFIDENTIAL www.mt.com/ac-expertise

Impact on Chemical Development



Generalization – non-experts need to use information-rich technologies



JNDERSTAND

In-depth understanding – more and better information has to be available during entire development process



Faster decision making – quickly turn data into information to shorten your experiment timelines and seamless sharing across organization



Combination of information - more and more analytical (PAT) technologies are used to understand the process



Trends from a Vendor Perspective

- Products need to be easier to use, increasing adoption velocity
- Low training requirement for utilization
- Decreased product complexity (& facilitation), "turn it on & get started "
- Total solution robustness is mandatory
- Value based pricing essential (ROI needs to be short term and measurable)
- Bidirectional open software based on industry standard communications, data structures, etc. (OPC, RT analysis options and Allotrope.....)
- "Open" innovation model required that focuses on key customer issues
- Software, information and data communication surrounding the customer workflow to ELN, LIMS, etc.

Pfizer LOTF – Mettler Toledo Engagement



METTLER TOLEDO CONFIDENTIAL

Technology In Use



Identified strategic platforms for success

Ex: Need - Increase Development Productivity



Secrets of Success

Top Down + Bottom Up commitment

- Vision to change
- Alignment of a core team
- Change management
- Joint customer/ vendor management engagement
- Share knowledge/ financial risk (in some cases IP)
- Prototype lab
 - Various equipment vendor evaluated
 - Continual feedback (sometimes ugly)
 - Iterations
- Strong MTAC Engagement/Integration
 - Right person for the job MTAC change management
 - Invited to LOT department meetings
 - Badge to allow TAC into lab
 - Feedback to management
 - Quarterly Leadership meetings
 - Management survey to chemists and feedback to MT

Pfizer & Other LOTF - A Living Organism



Requirements and priority continued to evolve throughout the implementation

Current BioPharma Business Dynamics



All supported by proactive change management

Strategic Alliance Driven Innovation



METTLER TOLEDO CONFIDENTIAL

Mettler-Toledo AutoChem Core Competencies

- in-Situ Analytics technology / know-how
 - FTIR for reaction and process monitoring
 - Probe based particle characterization and imaging
- Probe technology (analytical, performance, sealing, vessel interface, robustness cleaning, safety)
- Automated Lab Reactors (innovations in heating, cooling, dosing and stirring control)
- Calorimetry
 - Heat Flux an emerging technology that delivers high accuracy, direct energy measurement
 - Heat Flow
- in-Situ Sampling probe (Pfastrack/EasySampler)
- Software (UI, digital and analog signal processing algorithms, applications, control algorithms)
- World class technology and application experts with industry experience

MT: Open Innovation Model in Early Development



Conclusions

- Collaborations provide an opportunity develop key enabling technology that directly addresses important gaps in customer processes
 - Allows the vendor to intimately understand the "real" needs and rapid communications on "fit-gap" so in the end the customer gains a key solution
 - Cost and time frame effective (when considering the ENTIRE product in the end)
- Project priority must be have the same level of importance in both organizations. There must be a strategic fit
- The vendor needs to constantly assess the general marketability of the commercialized product More than one partner customer needs to be involved......but not too many
- Allows development of vendor's corporate technology vision with inclusion of significant customer input
- Industrial funding on the million dollar magnitude is no longer available Sharing resources and de-risking new technology development is a beneficial approach from both sides.
- Changes the relationship from vendor-customer to partners allowing for a far greater ownership of equipment roll out and initiative sustainment